Evidence map›Paper›PMID 26968791›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.

Kasey J Leger, Kara Cushing-Haugen, John A Hansen, Wenhong Fan, Wendy M Leisenring, Paul J Martin, Lue Ping Zhao, Eric J Chow

Open access · greenAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Cardioprotection of High-Risk Individuals.Heart failure clinics · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kasey J LegerDepartment of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington.
Kara Cushing-HaugenPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
John A HansenClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Wenhong FanPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Wendy M LeisenringPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
Lue Ping ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Eric J ChowDepartment of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: ericchow@u.washington.edu.
Fred Hutch Cancer Center · USSeattle Children's Hospital · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Whole Genome Association Analysis of Hematopoietic Cell Transplant (HCT) OutcomeR01HL105914 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MARTIN, PAUL J · 2011 to 2019
$9.8M
Determinants of late cardiovascular morbidity among survivors of hematopoietic ceK07CA151775 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2011 to 2015
$755k
Analysis of Morbidity and Mortality Among Hematopoietic Cell Transplantation SurvR03CA167451 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2013 to 2014
$173k
NCI NIH HHS K07 CA151775NCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R03 CA167451NHLBI NIH HHS R01 HL105914
6 · The paper itself

Abstract

Cardiomyopathy has been recognized as a complication after hematopoietic cell transplantation (HCT). Using a nested case-cohort design, we examined the relationships between demographic, therapeutic, and selected cardiovascular disease risk factors among ≥1-year HCT survivors who developed cardiomyopathy before (n = 43) or after (n = 89) 1 year from HCT as compared to a randomly selected subcohort of survivors without cardiomyopathy (n = 444). Genomic data were available for 79 cases and 267 noncases. Clinical and genetic covariates were examined for association with the risk of early or late cardiomyopathy. Clinical risk factors associated with both early- and late-onset cardiomyopathy included anthracycline exposure ≥250 mg/m(2) and pre-existing hypertension. Among late-onset cardiomyopathy cases, the development of diabetes and ischemic heart disease further increased risk. We replicated several previously reported genetic associations among early-onset cardiomyopathy cases, including rs1786814 in CELF4, rs2232228 in HAS3, and rs17863783 in UGT1A6. None of these markers were associated with risk of late-onset cardiomyopathy. A combination of demographic, treatment, and clinical covariates predicted early-onset cardiomyopathy with reasonable accuracy (area under the curve [AUC], .76; 95% confidence interval [CI], .68 to .83), but prediction of late cardiomyopathy was poor (AUC, .59; 95% CI .53 to .67). The addition of genetic polymorphisms with marginal associations (odds ratios ≥1.3) did not enhance prediction for either early- or late-onset cardiomyopathy. Conventional cardiovascular risk factors influence the risk of both early- and late-onset cardiomyopathy in HCT survivors. Although certain genetic markers may influence the risk of early-onset disease, further work is required to validate previously reported findings and to determine how genetic information should be incorporated into clinically useful risk prediction models.

Indexed as

Risk AssessmentSurvivorsAdultAnthracyclinesCardiomyopathiesCase-Control StudiesDiabetes MellitusGenetic Predisposition to DiseaseHematopoietic Stem Cell TransplantationHumansHypertensionMiddle AgedMyocardial IschemiaPredictive Value of TestsRisk FactorsTime FactorsAnthracyclinesCardiomyopathyHeart failureHypertensionSingle nucleotide polymorphismSurvivor

Identifiers

PMID26968791
PMCPMC4977273
OpenAlexW2296046182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.